Related references
Note: Only part of the references are listed.Investigation of Gender Heterogeneity in the Associations of Serum Phosphorus With Incident Coronary Artery Disease and All-Cause Mortality
Stephen J. Onufrak et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2009)
Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community
Majd A. I. Mirza et al.
ATHEROSCLEROSIS (2009)
Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population
Majd A. I. Mirza et al.
ATHEROSCLEROSIS (2009)
Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease
Orlando M. Gutierrez et al.
CIRCULATION (2009)
Chronic kidney disease, hypovitaminosis D, and mortality in the United States
Rajnish Mehrotra et al.
KIDNEY INTERNATIONAL (2009)
Relationship between circulating FGF23 and total body atherosclerosis in the community
Majd A. I. Mirza et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients
Guillaume Jean et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis
Orlando M. Gutierrez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The parathyroid is a target organ for FGF23 in rats
Iddo Z. Ben-Dov et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Vitamin D levels and early mortality among incident hemodialysis patients
M. Wolf et al.
KIDNEY INTERNATIONAL (2007)
Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase expression in cultured bovine parathyroid cells
Tijana Krajisnik et al.
JOURNAL OF ENDOCRINOLOGY (2007)
Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients
K. Kalantar-Zadeh et al.
KIDNEY INTERNATIONAL (2006)
Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: Improving global outcomes (KDIGO)
S. Moe et al.
KIDNEY INTERNATIONAL (2006)
Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia
Erik A. Imel et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa
T Shimada et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis
GA Block et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers
T Larsson et al.
KIDNEY INTERNATIONAL (2003)
Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia
Y Yamazaki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
T Shimada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
KE White et al.
NATURE GENETICS (2000)